# US 2022/0088145 A1 · Immunotherapy for the treatment and prevention of inflammatory bowel disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0088145 A1
- Document ID: US20220088145A1
- Status: Published application
- Kind: A1
- Application number: 17/426,234
- Filed: 2020-02-07
- Published: 2022-03-24
- Earliest claimed: 2019-02-08
- Assignees: The UAB Research Foundation
- Applicants: The Uab Research Foundation
- Inventors: Charles O. Elson; Wayne Duck; Qing Zhao; Katie Alexander
- Web page: https://patentgrep.com/patent/US20220088145A1

## CPC

- A61K 38/2013: {IL-2}
- A61K 31/155: Amidines ([IMAGE cpc-sch-A61K-1029.gif]), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61K 38/164: {from bacteria}
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07K 14/195: from bacteria
- A61K 2039/55516: {Proteins; Peptides}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Provided herein are methods and compositions for treating and preventing inflammatory bowel disease.

## Claims

### Claim 1

A method for treating or preventing inflammatory bowel disease comprising administering to a subject having inflammatory bowel disease or at risk of developing inflammatory bowel disease
a) an effective amount of a polypeptide comprising one or more flagellin T-cell receptor (TCR) epitopes; and
b) an effective amount of an agent that reduces flagellin antigen-specific memory T cells and/or increases regulatory T cells in the subject.

### Claim 2

A method for delaying or reducing the intensity of a relapse or flare of an inflammatory bowel disease in a subject comprising administering to a subject
a) an effective amount of a polypeptide comprising one or more flagellin T-cell receptor (TCR) epitopes; and
b) an effective amount of an agent that increases regulatory T cells in the subject.

### Claim 3 (depends on 1)

The method of claim 1, wherein the agent that reduces flagellin antigen-specific memory T cells and/or increases regulatory T cells in the subject is selected from the group consisting of a mutant IL-2 polypeptide, a metabolic inhibitor and a combination thereof.

### Claim 4 (depends on 1)

The method of claim 1, wherein the inflammatory bowel disease is Crohn's disease or ulcerative colitis.

### Claim 5

(canceled)

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The method of claim 1, wherein the one or more TCR epitopes activate flagellin-specific CD4+ T cells.

### Claim 8 (depends on 3)

The method of claim 3, wherein the metabolic inhibitor inactivates flagellin-specific activated T cells.

### Claim 9 (depends on 3)

The method of claim 3, wherein the metabolic inhibitor is an FK506-binding protein 12-rapamycin-associated protein 1 (mTOR) inhibitor.

### Claim 10 (depends on 9)

The method of claim 9, wherein the mTOR inhibitor is rapamycin.

### Claim 11 (depends on 1)

The method of claim 1, further comprising administering a protein kinase AMP-activated catalytic subunit alpha 1 (AMPK) activator to the subject.

### Claim 12 (depends on 11)

The method of claim 11, wherein the AMPK activator is metformin.

### Claim 13 (depends on 1)

The method of claim 1, wherein an increase in Treg cells and/or a decrease in memory (TM) cells occurs in the subject

### Claim 14

(canceled)

### Claim 15 (depends on 1)

The method of claim 1, wherein the polypeptide comprises two or more flagellin TCR epitopes.

### Claim 16 (depends on 1)

The method of claim 1, wherein the subject has an increased anti-flagellin response as compared to a control.

### Claim 17

(canceled)

### Claim 18

(canceled)

### Claim 19 (depends on 1)

The method of claim 1, wherein the polypeptide comprises one or more flagellin T-cell receptor (TCR) epitopes selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 6, SEQ ID NO: 7 SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO; 27, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, and SEQ ID NO: 37.

### Claim 20 (depends on 1)

The method of claim 1, wherein the polypeptide comprises one or more epitopes comprising SEQ ID NO: 1 (DMATEMVKYSNANILSQAGQ).

### Claim 21 (depends on 20)

The method of claim 20, wherein the polypeptide further comprises SEQ ID NO: 2 (ISQAVHAAHAEINEAGR).

### Claim 22 (depends on 20)

The method of claim 20, wherein the polypeptide further comprises SEQ ID NO: 3 (EAWGALANWAVDSA).

### Claim 23 (depends on 22)

The method of claim 22, wherein the polypeptide comprises SEQ ID NO: 4.

### Claim 24 (depends on 1)

The method of claim 1, wherein the polypeptide comprises SEQ ID NO: 6 (MVVQHNMQAMNANRMLNVTT), SEQ ID NO: 7 (LTEVHSMLQRMNELAVQASNG), SEQ ID NO: 8 (MVVQHNMTAANANRM), and/or SEQ ID NO: 9 (GETHSILQRMNELATQAAN).

### Claim 25 (depends on 24)

The method of claim 24, wherein the polypeptide comprises SEQ ID NO: 5.

### Claim 26 (depends on 1)

The method of claim 1, wherein a nucleic acid encoding the polypeptide comprising one or more flagellin T-cell receptor (TCR) epitopes and/or a nucleic acid encoding the mutant IL-2 polypeptide is administered to the subject.

### Claim 27 (depends on 26)

The method of claim 26, wherein the nucleic acid is in a vector.

### Claim 28

(canceled)

### Claim 29

A polypeptide comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 4 or SEQ ID NO: 5, wherein the polypeptide is not a full-length flagellin polypeptide sequence.

### Claim 30 (depends on 28)

A nucleic acid encoding the polypeptide of claim 28.

### Claim 31 (depends on 30)

A vector comprising the nucleic acid of claim 30.
